Latest Pharma and Biotech News
Biotechnology
26 November 2024 US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement.
Today's issue
Refine Search
Biotechnology
US biotech major Biogen has appointed Adam Keeney as executive vice president, head of corporate development effective April 17, 2023, adding a new face to its business development team. 5 April 2023
Pharmaceutical
The value of treatments for obesity is set to grow considerably in the next decade, with industry analyst GlobalData forecasting a market value of around $37 billion by 2031. 5 April 2023
Pharmaceutical
A Citizen Petition (CP) has been filed on behalf of Swiss biotech Idorsia Pharmaceuticals, urging the USA’s Drug Enforcement Administration (DEA) to de-schedule the dual orexin receptor antagonist (DORA) class of chronic insomnia medications based on a review of evidence from available data, including post-marketing surveillance data. 5 April 2023
Biotechnology
The US Food and Drug Administration (FDA) has placed a partial clinical hold on all trials of Gossamer Bio’s GB5121, in response to serious adverse events that have been observed in the Phase Ib/II STAR-CNS study, including atrial fibrillation, a sudden death event and a fatal intracranial hemorrhage. 5 April 2023
Pharmaceutical
The long-rumored acquisition of US biotech Seagen was finally announced in March, albeit it was not long-time suitor Merck & Co behind the deal, but rather fellow US pharma giant Pfizer. 4 April 2023
Pharmaceutical
Spanish epigenetics firm Oryzon Genomics has announced encouraging results from a planned interim analysis of the Phase IIb PORTICO study. 4 April 2023
Biotechnology
Wuppertal, Germany-based infectious disease drug developer AiCuris Anti-infective Cures today announced the appointment of Larry Edwards as chief executive (CEO), effective April 1, 2023. 4 April 2023
Biotechnology
Privately-held US precision oncology company Scorpion Therapeutics has announced a deal with French drugmaker Pierre Fabre. 4 April 2023
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Padcev (enfortumab vedotin-ejfv) with Keytruda (pembrolizumab), with the decision coming ahead of anticipated date of April 21. 4 April 2023
Pharmaceutical
Dermatology company Botanix Pharmaceuticals has safely navigated the US Food and Drug Administration (FDA) mid-cycle review with sofpironium bromide. 4 April 2023
Biotechnology
French drugmaker Sanofi has announced the publication of data from studies on its hemophilia candidate fitusiran in two medical journals. 4 April 2023
Pharmaceutical
The administrators of the USA’s public insurance scheme, Medicare, are getting ready to implement the measures included in the Inflation Reduction Act. 4 April 2023
Biotechnology
OncoSec Medical closed down almost 50% on Monday and fell a further 6% to $1.22 pre-market today, after the company announced primary endpoint data from the Phase II KEYNOTE-695 clinical trial that missed its goals. 4 April 2023
Biotechnology
Austrian drug discovery company Quantro Therapeutics has appointed Dr Michael Bauer as the firm’s chief executive (CEO), effective May 1, 2023. 4 April 2023
Biotechnology
The late-breaking data on AbbVie’s (NYSE: ABBV) blocker Skyrizi (risankizumab) in plaque psoriasis (PsO) that was presented at the recently concluded American Academy of Dermatology (AAD) Annual Meeting is expected to help Skyrizi’s positioning in the crowded PsO biologics space. 4 April 2023
Biotechnology
Continuing to invest the massive profits generated from its COVID-19 vaccine Comirnaty success, German biotech BioNTech has signed up for another oncology collaboration. 3 April 2023
Pharmaceutical
Shares in Sweden’s Asarina Pharma looked set to close more than 2% higher based on results from its Phase IIa study of the endogenous neurosteroid sepranolone for the treatment of Tourette syndrome. 3 April 2023
Biotechnology
US drugmaker Eli Lilly has again shown that Eisai and Biogen are not the only players in town in the Alzheimer’s space. 3 April 2023
Pharmaceutical
Japanese drugmaker Eisai (TYO: 4523) has entered into an agreement with the National Cancer Center to collaborate on investigator-initiated clinical research for the EZH2 inhibitor Tazverik (tazemetostat hydrobromide) based on “Patient-Proposed Healthcare Services” system, which will be conducted by the National Cancer Center Hospital. 3 April 2023
Pharmaceutical
Karim Mikhail is to resign as president and chief executive of Amarin Corp, the Ireland-headquartered fish oil-based heart drug specialist, according to a US Securities and Exchange Commission filing. 3 April 2023
All news
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Pharmaceutical
Japanese drugmaker Otsuka has announced the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labor and Welfare (MHLW) for the manufacture and sale in Japan of bempedoic acid - trade name Nexletol in Japan - for the treatment of hypercholesterolemia and familial hypercholesterolemia. 27 November 2024
Pharmaceutical
Berlin, Germany-based Eckert & Ziegler Radiopharma has received approval of its proprietary non-carrier added Lutetium-177 chloride, Theralugand, by the European Commission (EC). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Pharmaceutical
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) today announced that Dr Thomas Schinecker, chief executive (CEO) of Swiss pharma giant Roche (ROG: SIX), will take up the post as president of the trade association effective January 1, 2025. 26 November 2024
Pharmaceutical
US central nervous system (CNS) disorders specialist Axsome Therapeutics today released encouraging late-stage results for its narcolepsy candidate AXS-12 (reboxetine), sending its shares edging up 2.6% to $100.00 in pre-market activity. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Pharmaceutical
Shares in US biotech major Amgen were 11% lower early on Tuesday. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Biotechnology
South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with commitments and designated co-investments totalling $1.02 billion. 26 November 2024
Biotechnology
Pyxis Oncology has announced encouraging preliminary data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors. 26 November 2024
Biotechnology
The Phase III SKYSCRAPER-01 trial has missed its primary endpoint, Swiss cancer giant Roche has reported. 26 November 2024
Pharmaceutical
Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its investigational assets related to the HTI therapeutic HIV vaccine by US antiviral specialist Gilead Sciences. 26 November 2024
Biotechnology
US biopharma Biohaven has provided an update regarding the taldefgrobep alfa development programs in spinal muscular atrophy (SMA) and obesity. 25 November 2024
Biotechnology
Cassava Sciences, a US biotech developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, was trading 83% lower at midday on Thursday. 25 November 2024
Pharmaceutical
Positive top-line results from the Phase III ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) III or IV at high risk of mortality, were released today by US pharma giant Merck & Co. 25 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze